Immunovant (IMVT) Competitors $16.09 +0.38 (+2.42%) Closing price 08/4/2025 04:00 PM EasternExtended Trading$16.33 +0.24 (+1.49%) As of 04:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMVT vs. SLNO, QGEN, VTRS, ASND, BBIO, VRNA, BPMC, LEGN, ROIV, and RGCShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Soleno Therapeutics (SLNO), QIAGEN (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Roivant Sciences (ROIV), and Regencell Bioscience (RGC). Immunovant vs. Its Competitors Soleno Therapeutics QIAGEN Viatris Ascendis Pharma A/S BridgeBio Pharma Verona Pharma PLC American Depositary Share Blueprint Medicines Legend Biotech Roivant Sciences Regencell Bioscience Soleno Therapeutics (NASDAQ:SLNO) and Immunovant (NASDAQ:IMVT) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability. Does the media prefer SLNO or IMVT? In the previous week, Soleno Therapeutics had 1 more articles in the media than Immunovant. MarketBeat recorded 9 mentions for Soleno Therapeutics and 8 mentions for Immunovant. Soleno Therapeutics' average media sentiment score of 1.40 beat Immunovant's score of 0.63 indicating that Soleno Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Soleno Therapeutics 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer SLNO or IMVT? Soleno Therapeutics currently has a consensus target price of $108.70, suggesting a potential upside of 29.22%. Immunovant has a consensus target price of $36.40, suggesting a potential upside of 126.23%. Given Immunovant's higher possible upside, analysts plainly believe Immunovant is more favorable than Soleno Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Soleno Therapeutics 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Immunovant 0 Sell rating(s) 3 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.82 Which has more volatility & risk, SLNO or IMVT? Soleno Therapeutics has a beta of -2.56, indicating that its stock price is 356% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, indicating that its stock price is 34% less volatile than the S&P 500. Do insiders & institutionals hold more shares of SLNO or IMVT? 97.4% of Soleno Therapeutics shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 6.4% of Soleno Therapeutics shares are held by insiders. Comparatively, 1.8% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is SLNO or IMVT more profitable? Soleno Therapeutics' return on equity of -77.52% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Soleno TherapeuticsN/A -77.52% -63.44% Immunovant N/A -80.60%-71.89% Which has higher valuation and earnings, SLNO or IMVT? Soleno Therapeutics is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSoleno TherapeuticsN/AN/A-$175.85M-$4.62-18.21ImmunovantN/AN/A-$413.84M-$2.74-5.87 SummarySoleno Therapeutics beats Immunovant on 9 of the 13 factors compared between the two stocks. Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.69B$3.02B$5.51B$9.35BDividend YieldN/A2.46%4.74%4.16%P/E Ratio-5.8718.0629.1824.41Price / SalesN/A273.22435.00101.08Price / CashN/A40.5624.4827.20Price / Book3.878.628.485.77Net Income-$413.84M-$54.98M$3.24B$264.99M7 Day Performance-3.36%-0.87%0.64%-0.68%1 Month Performance-4.25%16.08%7.95%7.08%1 Year Performance-39.76%14.18%30.37%23.80% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.6227 of 5 stars$16.09+2.4%$36.40+126.2%-42.3%$2.69BN/A-5.87120SLNOSoleno Therapeutics4.287 of 5 stars$85.25-1.4%$108.70+27.5%+72.6%$4.36BN/A0.0030Positive NewsUpcoming EarningsQGENQIAGEN3.2215 of 5 stars$51.00-1.5%$49.40-3.1%+11.7%$11.51B$1.98B22.405,765Analyst UpgradeVTRSViatris2.2164 of 5 stars$9.26-1.6%$10.40+12.3%-24.7%$11.04B$14.74B-2.9232,000Upcoming EarningsShort Interest ↑ASNDAscendis Pharma A/S2.4963 of 5 stars$164.16-2.0%$223.07+35.9%+39.2%$10.24B$393.54M0.001,017Upcoming EarningsBBIOBridgeBio Pharma4.7738 of 5 stars$46.23-0.2%$61.50+33.0%+82.4%$8.79B$221.90M0.00400VRNAVerona Pharma PLC American Depositary Share2.012 of 5 stars$105.09-0.2%$109.00+3.7%+401.8%$8.54B$118.54M-52.5530Positive NewsUpcoming EarningsBPMCBlueprint Medicines0.7055 of 5 stars$129.46flat$128.25-0.9%N/A$8.36B$562.12M-52.41640Upcoming EarningsLEGNLegend Biotech3.712 of 5 stars$41.51-4.3%$73.33+76.7%-29.7%$7.97B$627.24M0.002,609News CoveragePositive NewsUpcoming EarningsROIVRoivant Sciences2.2365 of 5 stars$11.35-1.7%$16.50+45.4%+9.5%$7.85B$29.05M0.00860Upcoming EarningsRGCRegencell Bioscience0.0422 of 5 stars$13.80-8.3%N/AN/A$7.44BN/A0.0010Positive News Related Companies and Tools Related Companies SLNO Competitors QGEN Competitors VTRS Competitors ASND Competitors BBIO Competitors VRNA Competitors BPMC Competitors LEGN Competitors ROIV Competitors RGC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMVT) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
